SynthesisPaediatric respiratory reviews2021
Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation.
Synthesis in Paediatric respiratory reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05560906 (Study of Virus-specific Lymphocytic Cell Populations in Non-invasive Nasal Mucosa Samples of MIS-C Patients, and Intra-population Shifts in Inflammatory Tissues in the Acute Phase of MIS-C and in Health), which is not on this map. Cited by 224 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study of Virus-specific Lymphocytic Cell Populations in Non-invasive Nasal Mucosa Samples of MIS-C Patients, and Intra-population Shifts in Inflammatory Tissues in the Acute Phase of MIS-C and in Health
Who cites it
224 citing papers in PubMed, 6 syntheses or guidelines pooled it, 368 citations in OpenAlex.
- Prevalence, Comparative Risk, and Predictors of Shock in Children With Multisystem Inflammatory Syndrome Associated With COVID-19: A Systematic Review and Meta-Analysis.Journal of paediatrics and child health · 2026Pooled it
- Effectiveness of early Anakinra on cardiac function in children with multisystem inflammatory syndrome of COVID-19: a systematic review.BMC infectious diseases · 2024Pooled it
- COVID-19 in patients with Down syndrome: A systematic review.Immunity, inflammation and disease · 2024Pooled it
- Prevalence and related factors of child posttraumatic stress disorder during COVID-19 pandemic: A systematic review and meta-analysis.European psychiatry : the journal of the Association of European Psychiatrists · 2022Pooled it
- Risk Factors for Severe COVID-19 in Children: A Systematic Review and Meta-Analysis.Journal of Korean medical science · 2022Pooled it
- Update in Hyperferritinemic Syndromes: Recognition and Management - A Scoping Review.The Brown journal of hospital medicine · 2022Pooled it
- Efficacy, immunogenicity and safety of CoronaVac® in children and adolescents aged 6 months to 17 years: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial.Nature communications · 2024Trial
- Management of long COVID-19 in children and adolescents: from diagnosis to therapeutically approaches.Annals of medicine · 2026Review
- Long-Term Respiratory Outcomes in Pediatric Patients Following COVID-19 Infection and Multisystem Inflammatory Syndrome in Children (MIS-C).Biomedicines · 2026Article
- Trismus and Retropharyngeal Inflammation Revealing Multisystem Inflammatory Syndrome in Children: A Case Report.Cureus · 2026Article
- Echocardiographic assessment of cardiac involvement in pediatric COVID-19 patients: a cross-sectional study.BMC pediatrics · 2026Article
- Low ICU Admission and Excellent Outcomes in MIS-C: A Swedish Study From an Open Society.Acta paediatrica (Oslo, Norway : 1992) · 2026Article
- A rare case of unusual anti-tuberculosis drug reaction in disseminated tuberculosis with pre-existing Multisystem Inflammatory Syndrome in Children (MIS-C).BMC infectious diseases · 2026Article
- Prognostic models of multisystem inflammatory syndrome severity according to resource availability in healthcare facilities in Ukraine.Frontiers in pediatrics · 2026Article
- Case Report: MIS-C precipitating DKA and renal failure in a morbidly obese male with type 2 diabetes mellitus.Frontiers in pediatrics · 2026Article
- MIS-C: Diagnosis, Management, and Outcomes.Open forum infectious diseases · 2026Review
- Multisystem inflammatory syndrome in children featuring ataxia and papilledema: a case report.Journal of medical case reports · 2025Article
- Incidence, Clinical Profile, and Cardiac Manifestations of MIS-C in Children in Kuwait.Diagnostics (Basel, Switzerland) · 2025Article
- Predictors of lethal outcome in patients with immunoinflammatory diseases hospitalized in the intensive care unit.World journal of critical care medicine · 2025Article
- Comparison of Immunomodulatory Therapies for Cardiovascular Clinical and Inflammatory Markers Outcomes in Mild to Moderately Ill Hospitalized Multisystem Inflammatory Syndrome in Children Patients.Journal of cardiovascular development and disease · 2025Article
164 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multisystem Inflammatory Syndrome in Children (MIS-C) is a new phenomenon reported worldwide with temporal association with Covid-19. The objective of this paper is to evaluate reported cases in children and adolescents. From 1726 papers, 35 documented papers related to MIS-C cases identified 783 individual cases of MIS-C between March-June 2020; with 55% being male (n = 435) and a median age of 8.6 years (IQR, 7-10 years; range 3 months-20 years). Patients with MIS-C were noted to have a high frequency of gastrointestinal symptoms (71%) including abdominal pain (34%) and diarrhea (27%). Cough and respiratory distress were reported in 4.5% and 9.6% cases respectively. Blood parameters showed neutrophilia in 345/418 (83%) of cases and a high CRP in 587/626 (94%). 362/619 (59%) cases were SARS-CoV-2 infection positive (serology or PCR) however only 41% demonstrated pulmonary changes on chest imaging. Severity of illness was high with 68% cases requiring intensive care admission; 63% requiring inotropic support; 244/783 (28%) cases needing some form of respiratory support (138 mechanically ventilated), and 31 required extra-corporeal membrane oxygenation. Treatment strategies included intravenous immunoglobulin (63%) and intravenous steroids (44%). 29 cases received Infliximab, 47 received IL1 (interleukin) receptor antagonist, and 47 received IL6-receptor antagonist. 12/783 (1.5%) children died. In summary, a higher incidence of gastrointestinal symptoms were noted in MIS-C. In contrast to acute Covid-19 infection in children, MIS-C appears to be a condition of higher severity with 68% of cases having required critical care support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.